News

Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being…
Read More...

Roche announced results from the second interim analysis of the phase IIIb STASEY study, which reinforce the safety profile of Hemlibra (emicizumab) characterised in the phase III HAVEN…
Read More...

Roche announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary…
Read More...

Amgen announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of…
Read More...

The Therapeutic Goods Administration (TGA) has granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19. It has…
Read More...

ProteinQure announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of…
Read More...

Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira …
Read More...

Kymera Therapeutics Inc. announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader…
Read More...

Moderna, Inc. and Laboratorios Farmacéuticos Rovi, S.A. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against…
Read More...

Pfizer Inc. announced it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need…
Read More...

Boehringer Ingelheim and Numab Therapeutics (Numab) announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects…
Read More...

Zymeworks Inc. announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional…
Read More...

Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The new trial will be conducted using the new COVID-19 drug…
Read More...

Moderna, Inc., announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Moderna’s second mRNA…
Read More...

Xencor, Inc. and Atreca, Inc. announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific…
Read More...

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543,…
Read More...

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance…
Read More...

Corvus Pharmaceuticals, Inc. announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five patients…
Read More...

Turning Point Therapeutics, Inc. and Zai Lab announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in…
Read More...

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75…
Read More...